Mutation Analysis (MutSig v2.0)
Lung Squamous Cell Carcinoma (Primary solid tumor)
21 April 2013  |  analyses__2013_04_21
Maintainer Information
Citation Information
doi:10.7908/C1QC01FM
Maintained by Dan DiCara (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Lung Squamous Cell Carcinoma (Primary solid tumor cohort) - 21 April 2013: Mutation Analysis (MutSig v2.0). Broad Institute of MIT and Harvard. doi:10.7908/C1QC01FM
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.

  • Working with individual set: LUSC-TP

  • Number of patients in set: 178

Input

The input for this pipeline is a set of individuals with the following files associated for each:

  1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

  2. A .wig file that contains information about the coverage of the sample.

Summary

  • MAF used for this analysis:LUSC-TP.final_analysis_set.maf

  • Significantly mutated genes (q ≤ 0.1): 92

  • Mutations seen in COSMIC: 353

  • Significantly mutated genes in COSMIC territory: 11

  • Genes with clustered mutations (≤ 3 aa apart): 615

  • Significantly mutated genesets: 17

  • Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

  • Read 178 MAFs of type "Broad"

  • Total number of mutations in input MAFs: 65305

  • After removing 2 mutations outside chr1-24: 65303

  • After removing 419 blacklisted mutations: 64884

  • After removing 588 noncoding mutations: 64296

Mutation Filtering

  • Number of mutations before filtering: 64296

  • After removing 343 mutations outside gene set: 63953

  • After removing 47 mutations outside category set: 63906

  • After removing 2 "impossible" mutations in

  • gene-patient-category bins of zero coverage: 63514

Results
Breakdown of Mutations by Type

Table 1.  Get Full Table Table representing breakdown of mutations by type.

type count
Frame_Shift_Del 513
Frame_Shift_Ins 119
In_Frame_Del 46
In_Frame_Ins 3
Missense_Mutation 42529
Nonsense_Mutation 3682
Nonstop_Mutation 55
Silent 15747
Splice_Site 1191
Translation_Start_Site 21
Total 63906
Breakdown of Mutation Rates by Category Type

Table 2.  Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category n N rate rate_per_mb relative_rate exp_ns_s_ratio
Tp*C->mut 12975 692977947 0.000019 19 2 3.3
(A/C/G)p*C->(A/T) 17466 1964339776 8.9e-06 8.9 0.96 2.6
(A/C/G)p*C->G 3307 1964339776 1.7e-06 1.7 0.18 4.9
A->mut 8800 2561387954 3.4e-06 3.4 0.37 3.9
indel+null 5565 5218705677 1.1e-06 1.1 0.12 NaN
double_null 45 5218705677 8.6e-09 0.0086 0.00093 NaN
Total 48158 5218705677 9.2e-06 9.2 1 3.5
Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1. 

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2.  Patients counts and rates file used to generate this plot: LUSC-TP.patients.counts_and_rates.txt

CoMut Plot

Figure 3.  Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

  • N = number of sequenced bases in this gene across the individual set

  • n = number of (nonsilent) mutations in this gene across the individual set

  • npat = number of patients (individuals) with at least one nonsilent mutation

  • nsite = number of unique sites having a non-silent mutation

  • nsil = number of silent mutations in this gene across the individual set

  • n1 = number of nonsilent mutations of type: Tp*C->mut

  • n2 = number of nonsilent mutations of type: (A/C/G)p*C->(A/T)

  • n3 = number of nonsilent mutations of type: (A/C/G)p*C->G

  • n4 = number of nonsilent mutations of type: A->mut

  • n5 = number of nonsilent mutations of type: indel+null

  • n6 = number of nonsilent mutations of type: double_null

  • p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene

  • p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

  • p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene

  • p_joint = p-value for clustering + conservation

  • p = p-value (overall)

  • q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3.  Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 92. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank gene description N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_classic p_ns_s p_cons p_joint p q
1 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 134387 26 26 23 1 5 5 2 2 12 0 5.33e-15 0.016 5.6e-06 0.000022 0.000 0.000
2 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 583734 29 27 16 1 20 4 0 5 0 0 2.17e-12 0.021 0.0046 4.8e-06 4.44e-16 4.00e-12
3 TP53 tumor protein p53 218677 147 141 98 7 9 42 17 32 47 0 <1.00e-15 4e-09 0 0 <1.00e-15 <4.50e-12
4 NFE2L2 nuclear factor (erythroid-derived 2)-like 2 318204 28 27 15 0 19 4 0 4 1 0 4.77e-15 0.007 0 0 <1.00e-15 <4.50e-12
5 TPTE transmembrane phosphatase with tensin homology 308873 30 24 29 2 10 4 2 9 5 0 6.66e-15 0.034 0.46 0.74 1.68e-13 6.05e-10
6 KEAP1 kelch-like ECH-associated protein 1 312991 24 22 21 0 9 9 2 2 2 0 4.31e-13 0.00021 0.24 0.078 1.08e-12 3.24e-09
7 SI sucrase-isomaltase (alpha-glucosidase) 995567 46 36 46 2 10 21 2 8 5 0 7.17e-12 0.0066 0.89 1 1.91e-10 4.91e-07
8 PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 214719 16 14 15 0 4 1 0 3 8 0 1.10e-10 0.1 0.49 0.082 2.39e-10 5.39e-07
9 TRIM58 tripartite motif-containing 58 195196 15 15 15 1 2 8 1 1 3 0 1.45e-09 0.052 0.72 0.16 5.40e-09 1.08e-05
10 OR5L2 olfactory receptor, family 5, subfamily L, member 2 167267 15 13 15 1 0 6 3 5 1 0 1.03e-09 0.068 0.5 0.7 1.58e-08 2.84e-05
11 FAM5C family with sequence similarity 5, member C 412431 28 27 28 3 3 15 1 9 0 0 1.80e-09 0.043 0.99 1 3.81e-08 6.18e-05
12 LRRC4C leucine rich repeat containing 4C 342685 19 17 19 1 5 8 1 4 1 0 1.92e-08 0.021 0.24 0.1 4.12e-08 6.18e-05
13 ZBBX zinc finger, B-box domain containing 437517 17 17 17 1 4 4 1 5 3 0 7.22e-08 0.13 0.76 0.076 1.10e-07 0.000153
14 DPPA4 developmental pluripotency associated 4 167827 12 12 12 0 4 3 1 0 4 0 1.26e-08 0.057 0.57 0.48 1.21e-07 0.000155
15 ASB5 ankyrin repeat and SOCS box-containing 5 180540 9 9 9 0 3 1 3 2 0 0 6.92e-06 0.14 0.0065 0.0014 1.88e-07 0.000225
16 PDYN prodynorphin 137367 11 10 11 1 2 6 2 1 0 0 5.57e-07 0.1 0.28 0.019 2.03e-07 0.000229
17 REG1B regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) 92608 13 11 11 2 6 4 0 2 1 0 1.31e-07 0.29 0.082 0.19 4.63e-07 0.000491
18 CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1 272922 15 15 15 0 0 11 1 3 0 0 1.77e-07 0.0059 0.95 0.21 6.72e-07 0.000672
19 CRB1 crumbs homolog 1 (Drosophila) 759065 27 23 27 2 8 6 1 9 3 0 1.90e-07 0.043 0.88 0.31 1.03e-06 0.000977
20 OR6F1 olfactory receptor, family 6, subfamily F, member 1 165718 13 13 13 2 2 6 1 4 0 0 3.48e-07 0.19 0.19 0.33 1.97e-06 0.00178
21 OR2T33 olfactory receptor, family 2, subfamily T, member 33 171450 15 14 15 3 2 7 1 4 1 0 2.50e-07 0.22 0.48 0.81 3.31e-06 0.00282
22 ESRRG estrogen-related receptor gamma 250009 12 12 12 1 2 5 1 2 2 0 1.41e-06 0.13 0.64 0.15 3.44e-06 0.00282
23 OR2G6 olfactory receptor, family 2, subfamily G, member 6 169883 17 16 17 4 3 6 1 7 0 0 2.58e-06 0.27 0.13 0.087 3.66e-06 0.00286
24 USP29 ubiquitin specific peptidase 29 493525 18 17 18 1 3 6 2 4 3 0 3.22e-07 0.075 0.36 0.79 4.14e-06 0.00310
25 REG3A regenerating islet-derived 3 alpha 97465 14 11 14 2 1 8 3 1 1 0 1.58e-06 0.16 0.79 0.18 4.62e-06 0.00333
26 PNLIPRP3 pancreatic lipase-related protein 3 257837 12 12 12 1 1 6 2 1 2 0 6.87e-07 0.33 0.27 0.52 5.71e-06 0.00396
27 MAGEB2 melanoma antigen family B, 2 133192 9 9 9 1 2 4 2 1 0 0 5.40e-07 0.26 0.63 0.81 6.81e-06 0.00445
28 SPHKAP SPHK1 interactor, AKAP domain containing 911279 36 27 36 3 5 17 5 8 1 0 4.43e-07 0.012 0.89 1 6.92e-06 0.00445
29 CFHR4 complement factor H-related 4 180409 10 10 10 1 0 4 1 3 2 0 9.01e-07 0.35 0.44 0.57 7.92e-06 0.00492
30 SLC13A1 solute carrier family 13 (sodium/sulfate symporters), member 1 326098 12 12 12 1 4 2 1 4 1 0 4.24e-06 0.15 0.59 0.15 9.90e-06 0.00593
31 OR4M2 olfactory receptor, family 4, subfamily M, member 2 168054 15 14 15 3 1 7 0 6 1 0 6.77e-07 0.31 0.48 1 1.03e-05 0.00593
32 ELTD1 EGF, latrophilin and seven transmembrane domain containing 1 365327 18 18 18 2 4 3 1 4 6 0 9.28e-07 0.2 0.84 0.75 1.06e-05 0.00593
33 CPS1 carbamoyl-phosphate synthetase 1, mitochondrial 828677 30 25 29 3 4 17 1 6 2 0 5.58e-06 0.038 0.86 0.13 1.11e-05 0.00593
34 OR51B2 olfactory receptor, family 51, subfamily B, member 2 166648 12 10 11 0 2 4 1 3 2 0 1.21e-06 0.045 0.54 0.61 1.12e-05 0.00593
35 TGIF2LX TGFB-induced factor homeobox 2-like, X-linked 129265 12 9 12 1 2 2 0 6 2 0 1.37e-06 0.21 0.59 0.58 1.19e-05 0.00610
CDKN2A

Figure S1.  This figure depicts the distribution of mutations and mutation types across the CDKN2A significant gene.

PIK3CA

Figure S2.  This figure depicts the distribution of mutations and mutation types across the PIK3CA significant gene.

TP53

Figure S3.  This figure depicts the distribution of mutations and mutation types across the TP53 significant gene.

NFE2L2

Figure S4.  This figure depicts the distribution of mutations and mutation types across the NFE2L2 significant gene.

TPTE

Figure S5.  This figure depicts the distribution of mutations and mutation types across the TPTE significant gene.

KEAP1

Figure S6.  This figure depicts the distribution of mutations and mutation types across the KEAP1 significant gene.

SI

Figure S7.  This figure depicts the distribution of mutations and mutation types across the SI significant gene.

PTEN

Figure S8.  This figure depicts the distribution of mutations and mutation types across the PTEN significant gene.

TRIM58

Figure S9.  This figure depicts the distribution of mutations and mutation types across the TRIM58 significant gene.

OR5L2

Figure S10.  This figure depicts the distribution of mutations and mutation types across the OR5L2 significant gene.

FAM5C

Figure S11.  This figure depicts the distribution of mutations and mutation types across the FAM5C significant gene.

LRRC4C

Figure S12.  This figure depicts the distribution of mutations and mutation types across the LRRC4C significant gene.

ZBBX

Figure S13.  This figure depicts the distribution of mutations and mutation types across the ZBBX significant gene.

DPPA4

Figure S14.  This figure depicts the distribution of mutations and mutation types across the DPPA4 significant gene.

ASB5

Figure S15.  This figure depicts the distribution of mutations and mutation types across the ASB5 significant gene.

REG1B

Figure S16.  This figure depicts the distribution of mutations and mutation types across the REG1B significant gene.

CYP11B1

Figure S17.  This figure depicts the distribution of mutations and mutation types across the CYP11B1 significant gene.

CRB1

Figure S18.  This figure depicts the distribution of mutations and mutation types across the CRB1 significant gene.

OR6F1

Figure S19.  This figure depicts the distribution of mutations and mutation types across the OR6F1 significant gene.

OR2T33

Figure S20.  This figure depicts the distribution of mutations and mutation types across the OR2T33 significant gene.

ESRRG

Figure S21.  This figure depicts the distribution of mutations and mutation types across the ESRRG significant gene.

OR2G6

Figure S22.  This figure depicts the distribution of mutations and mutation types across the OR2G6 significant gene.

USP29

Figure S23.  This figure depicts the distribution of mutations and mutation types across the USP29 significant gene.

REG3A

Figure S24.  This figure depicts the distribution of mutations and mutation types across the REG3A significant gene.

PNLIPRP3

Figure S25.  This figure depicts the distribution of mutations and mutation types across the PNLIPRP3 significant gene.

MAGEB2

Figure S26.  This figure depicts the distribution of mutations and mutation types across the MAGEB2 significant gene.

SPHKAP

Figure S27.  This figure depicts the distribution of mutations and mutation types across the SPHKAP significant gene.

CFHR4

Figure S28.  This figure depicts the distribution of mutations and mutation types across the CFHR4 significant gene.

SLC13A1

Figure S29.  This figure depicts the distribution of mutations and mutation types across the SLC13A1 significant gene.

OR4M2

Figure S30.  This figure depicts the distribution of mutations and mutation types across the OR4M2 significant gene.

ELTD1

Figure S31.  This figure depicts the distribution of mutations and mutation types across the ELTD1 significant gene.

CPS1

Figure S32.  This figure depicts the distribution of mutations and mutation types across the CPS1 significant gene.

OR51B2

Figure S33.  This figure depicts the distribution of mutations and mutation types across the OR51B2 significant gene.

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4.  Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 11. Number of genes displayed: 10

rank gene description n cos n_cos N_cos cos_ev p q
1 TP53 tumor protein p53 147 356 144 63368 25865 0 0
2 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 29 220 24 39160 9572 0 0
3 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 26 332 25 59096 559 0 0
4 PTEN phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 16 767 16 136526 579 0 0
5 HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 5 19 5 3382 1133 2.4e-10 2.2e-07
6 FBXW7 F-box and WD repeat domain containing 7 11 91 6 16198 220 1.4e-08 1e-05
7 RB1 retinoblastoma 1 (including osteosarcoma) 12 267 7 47526 17 4.2e-07 0.00027
8 HEPACAM2 HEPACAM family member 2 4 1 2 178 2 1.3e-06 0.00076
9 NF1 neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease) 22 285 6 50730 21 9.8e-06 0.0049
10 BRAF v-raf murine sarcoma viral oncogene homolog B1 8 89 4 15842 77 0.000017 0.0077

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5.  Get Full Table Genes with Clustered Mutations

num gene desc n mindist nmuts0 nmuts3 nmuts12 npairs0 npairs3 npairs12
11890 TP53 tumor protein p53 147 0 115 344 950 115 344 950
8725 PIK3CA phosphoinositide-3-kinase, catalytic, alpha polypeptide 29 0 50 93 112 50 93 112
7520 NFE2L2 nuclear factor (erythroid-derived 2)-like 2 28 0 32 112 189 32 112 189
5008 HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 36 0 9 14 19 9 14 19
12151 TTN titin 333 0 6 14 40 6 14 40
10005 RYR2 ryanodine receptor 2 (cardiac) 120 0 5 12 38 5 12 38
2802 CSMD3 CUB and Sushi multiple domains 3 120 0 4 16 41 4 16 41
3897 FAM135B family with sequence similarity 135, member B 49 0 4 9 19 4 9 19
9653 REG1B regenerating islet-derived 1 beta (pancreatic stone protein, pancreatic thread protein) 13 0 4 7 15 4 7 15
5033 HEATR7B2 HEAT repeat family member 7B2 32 0 4 6 14 4 6 14

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6.  Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 17. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 P53HYPOXIAPATHWAY Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 19 ABCB1(18), AKT1(1), ATM(8), BAX(1), CDKN1A(2), CPB2(3), CSNK1A1(2), CSNK1D(2), FHL2(1), GADD45A(1), HIF1A(1), IGFBP3(2), MAPK8(3), MDM2(2), NFKBIB(1), TP53(147) 5514084 195 151 146 10 27 58 18 40 50 2 2.8e-10 1.2e-15 2.2e-13
2 G1PATHWAY CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 25 ABL1(3), ATM(8), ATR(13), CCNA1(1), CCND1(1), CCNE1(3), CDKN1A(2), CDKN2A(26), CDKN2B(1), E2F1(2), HDAC1(2), RB1(12), SKP2(2), TFDP1(3), TGFB1(1), TGFB2(3), TP53(147) 7994705 230 156 178 17 29 69 22 40 70 0 2.6e-09 1.6e-15 2.2e-13
3 TIDPATHWAY On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 18 IFNG(1), IFNGR1(4), IFNGR2(1), IKBKB(2), JAK2(4), LIN7A(1), NFKB1(2), RB1(12), RELA(3), TNF(1), TNFRSF1A(2), TNFRSF1B(1), TP53(147), USH1C(7), WT1(4) 4825619 192 144 143 16 19 51 21 43 58 0 1.1e-07 1.8e-15 2.2e-13
4 RBPATHWAY The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH 12 ATM(8), CDC25B(2), CDC25C(1), CHEK1(5), MYT1(4), RB1(12), TP53(147), WEE1(4) 4677103 183 146 134 10 18 53 19 36 57 0 9.3e-09 2e-15 2.2e-13
5 SA_G1_AND_S_PHASES Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 15 ARF1(1), CCND1(1), CDKN1A(2), CDKN2A(26), CFL1(2), E2F1(2), MDM2(2), NXT1(1), PRB1(5), TP53(147) 2143952 189 149 137 12 18 56 19 37 59 0 2.5e-10 2.4e-15 2.2e-13
6 PLK3PATHWAY Active Plk3 phosphorylates CDC25c, blocking the G2/M transition, and phosphorylates p53 to induce apoptosis. ATM, ATR, CDC25C, CHEK1, CHEK2, CNK, TP53, YWHAH 7 ATM(8), ATR(13), CDC25C(1), CHEK1(5), CHEK2(3), TP53(147) 4260894 177 146 128 10 18 52 20 37 50 0 2.2e-07 2.4e-15 2.2e-13
7 TERTPATHWAY hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 7 HDAC1(2), MYC(1), SP1(2), SP3(1), TP53(147), WT1(4) 1863398 157 146 108 12 10 45 19 36 47 0 8.6e-07 2.6e-15 2.2e-13
8 RNAPATHWAY dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 9 CHUK(2), EIF2S2(1), MAP3K14(1), NFKB1(2), RELA(3), TP53(147) 2611540 156 141 107 10 11 43 18 34 50 0 1.7e-07 3.3e-15 2.4e-13
9 PMLPATHWAY Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 13 CREBBP(17), DAXX(3), HRAS(5), PAX3(4), RARA(1), RB1(12), SIRT1(1), SP100(3), TNF(1), TNFRSF1A(2), TNFRSF1B(1), TP53(147) 5020302 197 147 147 17 17 59 21 42 58 0 7.7e-08 3.4e-15 2.4e-13
10 TELPATHWAY Telomerase is a ribonucleotide protein that adds telomeric repeats to the 3' ends of chromosomes. AKT1, BCL2, EGFR, G22P1, HSPCA, IGF1R, KRAS2, MYC, POLR2A, PPP2CA, PRKCA, RB1, TEP1, TERF1, TERT, TNKS, TP53, XRCC5 15 AKT1(1), EGFR(7), IGF1R(1), MYC(1), POLR2A(2), PRKCA(5), RB1(12), TEP1(8), TERF1(3), TERT(3), TNKS(7), TP53(147), XRCC5(2) 7492174 199 149 149 17 24 56 18 42 59 0 1.4e-08 4e-15 2.5e-13

Table 7.  Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank geneset description genes N_genes mut_tally N n npat nsite nsil n1 n2 n3 n4 n5 n6 p_ns_s p q
1 HSA00627_1,4_DICHLOROBENZENE_DEGRADATION Genes involved in 1,4-dichlorobenzene degradation CMBL 1 CMBL(3) 134908 3 3 3 1 0 1 0 2 0 0 0.81 0.04 1
2 HSA00902_MONOTERPENOID_BIOSYNTHESIS Genes involved in monoterpenoid biosynthesis CYP2C19, CYP2C9 2 CYP2C19(9), CYP2C9(3) 536360 12 10 12 3 5 4 0 2 1 0 0.48 0.099 1
3 SA_G2_AND_M_PHASES Cdc25 activates the cdc2/cyclin B complex to induce the G2/M transition. CDC2, CDC25A, CDC25B, CDK7, CDKN1A, CHEK1, NEK1, WEE1 7 CDC25B(2), CDK7(1), CDKN1A(2), CHEK1(5), NEK1(3), WEE1(4) 1849805 17 17 17 1 7 5 1 3 1 0 0.1 0.24 1
4 HSA00750_VITAMIN_B6_METABOLISM Genes involved in vitamin B6 metabolism AOX1, PDXK, PDXP, PNPO, PSAT1 5 AOX1(13), PDXP(1), PSAT1(3) 1279971 17 16 17 2 6 5 0 5 1 0 0.13 0.28 1
5 HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM Genes involved in D-arginine and D-ornithine metabolism DAO 1 DAO(2) 191569 2 2 2 0 0 1 0 0 1 0 0.5 0.36 1
6 HSA00550_PEPTIDOGLYCAN_BIOSYNTHESIS Genes involved in peptidoglycan biosynthesis GLUL, PGLYRP2 2 GLUL(4), PGLYRP2(2) 477868 6 5 6 0 1 4 1 0 0 0 0.15 0.37 1
7 FBW7PATHWAY Cyclin E interacts with cell cycle checkpoint kinase cdk2 to allow transcription of genes required for S phase, including transcription of additional cyclin E. CCNE1, CDC34, CDK2, CUL1, E2F1, FBXW7, RB1, SKP1A, TFDP1 7 CCNE1(3), CUL1(4), E2F1(2), FBXW7(11), TFDP1(3) 1728213 23 23 21 4 6 8 3 1 5 0 0.26 0.43 1
8 P27PATHWAY p27 blocks the G1/S transition by inhibiting the checkpoint kinase cdk2/cyclin E and is inhibited by cdk2-mediated ubiquitination. CCNE1, CDK2, CDKN1B, CKS1B, CUL1, E2F1, NEDD8, RB1, RBX1, SKP1A, SKP2, TFDP1, UBE2M 11 CCNE1(3), CKS1B(1), CUL1(4), E2F1(2), RBX1(1), SKP2(2), TFDP1(3), UBE2M(1) 1813849 17 16 17 1 5 8 0 2 2 0 0.05 0.46 1
9 HSA00780_BIOTIN_METABOLISM Genes involved in biotin metabolism BTD, HLCS, SPCS1, SPCS3 4 BTD(2), HLCS(5), SPCS1(1), SPCS3(2) 816418 10 9 10 2 2 2 2 0 4 0 0.4 0.49 1
10 HSA00950_ALKALOID_BIOSYNTHESIS_I Genes involved in alkaloid biosynthesis I DDC, GOT1, GOT2, TAT, TYR 5 DDC(6), GOT2(3), TAT(1), TYR(10) 1245159 20 18 20 4 2 12 0 3 3 0 0.22 0.53 1
Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle